



Becton, Dickinson & Co. (BDX)

Updated May 7th, 2022 by Nathan Parsh

Key Metrics

Current Price:	\$258	5 Year CAGR Estimate:	9.7%	Market Cap:	\$73.5 B
Fair Value Price:	\$240	5 Year Growth Estimate:	10.0%	Ex-Dividend Date:	06/08/22
% Fair Value:	107%	5 Year Valuation Multiple Estimate:	-1.4%	Dividend Payment Date:	06/30/22
Dividend Yield:	1.3%	5 Year Price Target:	\$387	Years Of Dividend Growth:	50
Dividend Risk Score:	A	Retirement Suitability Score:	B	Rating:	Hold

Overview & Current Events

Becton, Dickinson & Co., or BD, is a global leader in the medical supply industry. The company was founded in 1897 and has 75,000 employees across 190 countries. The company generates about \$19 billion in annual revenue, with approximately 43% of revenues coming from outside of the U.S. BD is composed of three segments. Products sold by the Medical Division include needles for drug delivery systems, and surgical blades. The Life Sciences division provides products for the collection and transportation of diagnostic specimens. The Intervention segment includes several of the products produced by what used to be Bard.

On February 1st, 2022, BD's board of directors voted to approve the spinoff of the company's diabetes care business, which will be known as Embecta. The spinoff occurred on April 1st, 2022.

On May 5th, 2022, BD released earnings results for the second quarter of fiscal year 2022, which ended on March 31st, 2022 (the company's fiscal year ends September 30th, 2022). Revenue grew 2% to \$5 billion, topping estimates by \$230 million. Adjusted earnings-per-share of \$3.18 was essentially flat compared adjusted earnings-per-share of \$3.19 in the prior year, but was \$0.23 better than expected.

All results are listed on a currency neutral basis unless otherwise noted. Overall, U.S. grew 14% while international was down almost 10%. COVID-19 diagnostic revenue totaled \$214 million, or 4.3% of total revenue for the quarter. The Medical segment grew 6.4% to \$2.4 billion due once again to strength in Medication Delivery Solutions, Medical Management Solutions, and Pharmaceutical Systems. Life Science decreased 4.2% to \$1.5 billion. Demand for COVID-19 testing devices wasn't nearly as high as the prior year. Adjusting for this, base revenue was up 17.1%. Excluding COVID-19 related revenue, Integrated Diagnostic Solutions was up nearly 22% due to strong demand for specimen management products. Biosciences remain strong due to demand for research reagents and instruments as lab utilization levels normalize. Interventional was up 11.2% to \$1.1 billion as all three businesses performed very well. Surgery led the way with revenue of 17.5% due to more elective procedures being performed.

BD also provided an updated outlook for fiscal year 2022, with the company expecting revenue in the range of \$19.6 billion to \$19.8 billion, up from \$19.55 billion to \$19.75 billion and \$19.3 billion to \$19.5 billion previously. Adjusted earnings-per-share are now projected to be in a range of \$12.85 to \$13.00, compared to \$12.80 to \$13.00 and \$12.30 to \$12.50 previously. We have updated our forecast accordingly.

Growth on a Per-Share Basis

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2027
EPS	\$5.36	\$5.81	\$6.25	\$7.16	\$8.59	\$9.48	\$11.01	\$11.68	\$10.19	\$13.08	\$12.93	\$20.82
DPS	\$1.80	\$1.98	\$2.18	\$2.40	\$2.64	\$2.92	\$3.02	\$3.08	\$3.16	\$3.32	\$3.48	\$5.60
Shares¹	197	194	192	211	213	228	265	265	293	289	287	265

BD has increased earnings-per-share 10.4% per year over the past 10 years, and has grown earnings in 9 out of the last 10 years. We feel that BD can grow earnings at a rate of 10% per year through fiscal 2027 due to a combination of mid-single-digit organic sales growth, revenue gains due to Bard, and a lower projected tax rate.

¹ In millions of shares

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Becton, Dickinson & Co. (BDX)

Updated May 7th, 2022 by Nathan Parsh

Following a 4.8% increase for the December 31st, 2021 payment date, BD has now increased its dividend for 50 consecutive years. This makes the company a member of the Dividend Kings. While this is below the long-term average, investors should know that the Bard acquisition is the largest in BD's history and that 70% of the purchase price was paid for in cash. We believe that the company's dividend growth rate will eventually be more in line with its historical average once BD's cash position improves. BD has a low payout ratio leaving for plenty of room for additional increases.

Valuation Analysis

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	Now	2027
Avg. P/E	14.1	15.6	18.1	19.5	18.4	19.4	20.8	20.8	24.7	18.8	20.0	18.6
Avg. Yld.	2.4%	2.2%	1.9%	1.7%	1.7%	1.7%	1.3%	1.3%	1.3%	1.4%	1.3%	1.4%

BD's stock has declined \$13, or 4.8%, since our February 4th, 2022 report. Based off of estimates for fiscal year 2022, BD's stock currently has a price-to-earnings ratio of 20. Our target price-to-earnings ratio for fiscal year 2027 is 18.6, which matches the stock's 10-year average earnings multiple. Valuation could be a 1.4% headwind to annual returns over the next five years. BD's current yield of 1.3% is low by historical standards.

Safety, Quality, Competitive Advantage, & Recession Resiliency


Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2027
Payout	34%	34%	35%	34%	31%	31%	27%	26%	31%	25%	27%	27%

BD showed that it can perform well in less than ideal economic conditions during the last recession. The company's key competitive advantage is that its products are in high demand as medical devices and other healthcare products are still sought out during a recession. People will seek medical care regardless of how the economy is performing. This ability to grow or maintain earnings in any economic climate makes BD a quality company and a safe stock. The acquisition of Bard has added to both the top and bottom lines and increases the company's exposure to China.

Final Thoughts & Recommendation

Becton, Dickinson & Co. is expected to offer a total return of 9.7% annually over the next five years, up from 8.6% previously. This is due to a 10% expected earnings growth rate and a 1.3% starting dividend yield that are offset by a low single-digit headwind from valuation compression. COVID-19 remains a small part of BD's business at the moment, which will likely lead to several quarters of lower year-over-year results in certain areas of the company. However, nearly all other businesses are seeing solid growth rates, demonstrating the overall strength of BD. We have raised our five-year price target \$1 to \$387 due to EPS estimates for the fiscal year, but continue to view shares of BD as a hold due to projected returns. A small pullback would cause us to become more bullish on the stock.

Total Return Breakdown by Year



[Click here to rate and review this research report. Your feedback is important to us.](#)

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Becton, Dickinson & Co. (BDX)

Updated May 7th, 2022 by Nathan Parsh

Income Statement Metrics

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Revenue	7584	7708	8054	8446	10282	12483	12093	15983	17290	17117
Gross Profit	3959	3953	4171	4301	4695	5991	5965	7269	8288	7577
Gross Margin	52.2%	51.3%	51.8%	50.9%	45.7%	48.0%	49.3%	45.5%	47.9%	44.3%
SG&A Exp.	1824	1923	2422	2145	2563	3005	2953	4029	4334	4318
D&A Exp.	494	511	546	562	891	1114	1088	1978	2253	2154
Operating Profit	1665	1558	1255	1606	1500	2158	1832	2236	2238	1800
Operating Margin	22.0%	20.2%	15.6%	19.0%	14.6%	17.3%	15.1%	14.0%	12.9%	10.5%
Net Profit	1271	1170	1293	1185	695	976	1100	311	1233	874
Net Margin	16.8%	15.2%	16.1%	14.0%	6.8%	7.8%	9.1%	1.9%	7.1%	5.1%
Free Cash Flow	1117	1209	1131	1091	1133	1866	1823	1970	2373	2729
Income Tax	417	363	236	337	44	97	(124)	862	(57)	111

Balance Sheet Metrics

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Total Assets	10430	11361	12149	12447	26478	25586	37734	53904	51765	54012
Cash & Equivalents	1175	1671	1890	1861	1424	1541	14179	1140	536	2825
Accounts Receivable	1229	1250	1240	1187	1618	1618	1744	2319	2345	2398
Inventories	1245	1241	1402	1495	1959	1719	1818	2451	2579	2743
Goodwill & Int. Ass.	2106	2235	2315	2217	14924	13700	13456	40041	38353	37433
Total Liabilities	5602	7225	7107	7394	19313	17952	24786	32910	30683	30247
Accounts Payable	305	350	333	401	631	665	797	1106	1092	1355
Long-Term Debt	2720	4166	3970	3971	12822	11551	18870	21495	19390	17930
Shareholder's Equity	4828	4136	5042	5053	7165	7634	12946	20992	21080	23763
LTD/E Ratio	0.56	1.01	0.79	0.79	1.79	1.51	1.46	1.02	0.92	0.75

Profitability & Per Share Metrics

Year	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
Return on Assets	12.7%	10.7%	11.0%	9.6%	3.6%	3.7%	3.5%	0.7%	2.3%	1.7%
Return on Equity	24.8%	26.1%	28.2%	23.5%	11.4%	13.2%	10.7%	1.8%	5.9%	3.9%
ROIC	17.3%	14.8%	14.9%	13.1%	4.8%	5.0%	4.3%	0.8%	3.0%	2.1%
Shares Out.	197	194	192	211	213	228	265	265	293	289
Revenue/Share	33.52	36.85	40.43	42.72	49.55	57.38	54.09	60.40	62.92	60.61
FCF/Share	4.94	5.78	5.68	5.52	5.46	8.58	8.15	7.44	8.64	9.66

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.